Explore

Trendline Trendline
Amgen Launches Phase 3 Study for MariTide, Aiming to Revolutionize Obesity Treatment

Amgen Launches Phase 3 Study for MariTide, Aiming to Revolutionize Obesity Treatment

Amgen Launches Phase 3 Study for MariTide, Aiming to Revolutionize Obesity Treatment
Trendline Trendline
Bambusa Therapeutics Completes Enrollment for Atopic Dermatitis Drug Trial

Bambusa Therapeutics Completes Enrollment for Atopic Dermatitis Drug Trial

Bambusa Therapeutics Completes Enrollment for Atopic Dermatitis Drug Trial
Trendline Trendline
Corcept Therapeutics' ALS Drug Shows Promising Survival Benefits as Phase 3 Trial Approaches

Corcept Therapeutics' ALS Drug Shows Promising Survival Benefits as Phase 3 Trial Approaches

Corcept Therapeutics' ALS Drug Shows Promising Survival Benefits as Phase 3 Trial Approaches
Trendline Trendline
Corcept Therapeutics Reports Two-Year Survival Benefit in ALS Patients from Dazucorilant Phase 2 Study

Corcept Therapeutics Reports Two-Year Survival Benefit in ALS Patients from Dazucorilant Phase 2 Study

Corcept Therapeutics Reports Two-Year Survival Benefit in ALS Patients from Dazucorilant Phase 2 Study
Rapid Read Rapid Read
AI Research Uncovers Unreported GLP-1 Side Effects in Clinical Trials

AI Research Uncovers Unreported GLP-1 Side Effects in Clinical Trials

A new study using artificial intelligence has identified potential side effects of GLP-1 medications that were not reported in clinical trials. Conducted by researchers at Penn Engineering, the study analyzed 400,000 Reddit posts to identify patient-reported side effects. Commonly reported issues included nausea, vomiting, and constipation, aligning with clinical trial data. However, the study also found less common side effects such as menstrual irregularities and temperature-related symptoms. The research highlights the importance of patient-reported data in understanding the full spectrum of drug side effects.
Rapid Read Rapid Read
Researchers Uncover Ketamine's Mechanism for Depression Relief, Paving Way for New Treatments

Researchers Uncover Ketamine's Mechanism for Depression Relief, Paving Way for New Treatments

Researchers at Weill Cornell Medicine have made significant strides in understanding how ketamine provides rapid relief for treatment-resistant depression. The studies reveal that ketamine targets specific opioid receptors in the prefrontal cortex, a brain region crucial for emotion and behavior regulation. By briefly silencing these receptors, ketamine reactivates the prefrontal cortex, initiating an antidepressant effect. The research also highlights a novel 'cross-talk' between cell receptors, which is essential for maintaining ketamine's long-term benefits. This discovery has led to the development of a new drug combination that mimics ketamine's effects without its side effects, using lower doses of existing drugs. This breakthrough could lead to the creation of rapid-acting antidepressants that avoid the dissociative and addictive side effects associated with ketamine.
Trendline Trendline
Bambusa Therapeutics Completes Enrollment for Phase 1b/2a Trial of BBT001 for Atopic Dermatitis

Bambusa Therapeutics Completes Enrollment for Phase 1b/2a Trial of BBT001 for Atopic Dermatitis

Bambusa Therapeutics Completes Enrollment for Phase 1b/2a Trial of BBT001 for Atopic Dermatitis
Trendline Trendline
GSK and Alector Halt Alzheimer's Drug Trial After Efficacy Failure

GSK and Alector Halt Alzheimer's Drug Trial After Efficacy Failure

GSK and Alector Halt Alzheimer's Drug Trial After Efficacy Failure
Trendline Trendline
FDA Halts Newron's Schizophrenia Study After Patient Death, Safety Review Underway

FDA Halts Newron's Schizophrenia Study After Patient Death, Safety Review Underway

FDA Halts Newron's Schizophrenia Study After Patient Death, Safety Review Underway
Trendline Trendline
FDA's Real-Time Clinical Trial Initiative: AstraZeneca and Amgen to Pilot New Model

FDA's Real-Time Clinical Trial Initiative: AstraZeneca and Amgen to Pilot New Model

FDA's Real-Time Clinical Trial Initiative: AstraZeneca and Amgen to Pilot New Model
Rapid Read Rapid Read
Bambusa Therapeutics Completes Enrollment for BBT001 Trial in Atopic Dermatitis

Bambusa Therapeutics Completes Enrollment for BBT001 Trial in Atopic Dermatitis

Bambusa Therapeutics has announced the completion of patient enrollment for its Phase 1b/2a trial of BBT001, a bispecific antibody designed to treat moderate-to-severe atopic dermatitis (AD). The trial, conducted in New Zealand and the United States, is a randomized, placebo-controlled study focusing on the safety and tolerability of BBT001. The trial also explores efficacy through various biomarkers. BBT001 targets IL-4Rα and IL-31 signaling pathways, aiming to provide significant relief for patients with AD and other type 2 inflammatory skin diseases. The company plans to release topline results in mid-2026.
Trendline Trendline
Theradaptive Receives FDA Approval for Pivotal Study of OsteoAdapt SP in Spinal Fusion

Theradaptive Receives FDA Approval for Pivotal Study of OsteoAdapt SP in Spinal Fusion

Theradaptive Receives FDA Approval for Pivotal Study of OsteoAdapt SP in Spinal Fusion